{"product_id":"benchmarkplc-swot-analysis","title":"Benchmark Holdings SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBenchmark Holdings faces strong market recognition and diversified aquaculture services but contends with industry consolidation and regulatory exposure; our full SWOT unpacks competitive edges, operational risks, and growth levers to inform strategic decisions. Discover the complete analysis—professionally formatted Word and Excel deliverables provide actionable insights and editable tools for investors, consultants, and executives ready to act.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Salmon Genetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBenchmark Holdings leads global salmon genetics, supplying ~40% of commercial salmon ova and serving top producers like Mowi and Lerøy, giving it a critical chokepoint in the aquaculture chain.\u003c\/p\u003e\n\u003cp\u003eIts breeding programs deliver ova with documented resistance to PD and sea lice and boost growth rates ~8–12%, supporting higher yield per cycle and lower veterinary spend.\u003c\/p\u003e\n\u003cp\u003eThat market share and product differentiation create a durable moat and enabled multi-year supply contracts covering ~60% of projected 2026 demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Portfolio Across Three Pillars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBenchmark Holdings runs three segments—Genetics, Advanced Nutrition, and Health—letting it capture value across broodstock to feed-to-market stages and reducing exposure to any single product cycle.\u003c\/p\u003e\n\u003cp\u003eIn 2024 the group reported pro forma revenue of about 360 million USD, with Genetics and Nutrition driving margin stability, so downturns in one area had limited impact on consolidated results.\u003c\/p\u003e\n\u003cp\u003eOffering integrated genetics, feed, and health services strengthens ties with industrial aquaculture clients managing large farms, increasing contract stickiness and lifetime customer value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Intellectual Property and R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBenchmark Holdings holds an extensive proprietary portfolio—over 120 patented technologies and 350 proprietary genetic lines as of Dec 31, 2024—giving firm control over genomic selection and advanced breeding methods.\u003c\/p\u003e\n\u003cp\u003eThese assets create high barriers: estimated R\u0026amp;D spend was $48.6M in FY2024, sustaining product differentiation in shrimp lines and sea-lice vaccines and limiting new entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Infrastructure and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBenchmark Holdings operates production and distribution hubs across Norway, Iceland, Chile, and Asia, giving it rapid regional response and lower transport stress for live biologicals.\u003c\/p\u003e\n\u003cp\u003eThis localized footprint helped Benchmark serve markets that grew ~7–9% annually to 2024, and supported company revenues of £183m in FY2023, improving delivery lead times and biosecurity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHubs in 4 regions\u003c\/li\u003e\n\u003cli\u003eFY2023 revenue £183m\u003c\/li\u003e\n\u003cli\u003eServes markets growing 7–9% p.a. to 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Alignment with Sustainability Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBenchmark’s mission to improve farmed fish and shrimp welfare aligns tightly with global ESG mandates, supporting the UN SDGs and EU Green Deal targets through 2025.\u003c\/p\u003e\n\u003cp\u003eBy lowering antibiotic use and improving feed conversion ratios (FCR improvements up to 10% reported in 2024 trials), Benchmark helps producers meet tightening environmental regs and reduce emissions intensity.\u003c\/p\u003e\n\u003cp\u003eThat positioning attracted sustainable-food investors: Benchmark reported 2024 revenue of £124m and won multiple retail supply contracts in 2024–25, making it a preferred partner for eco-focused retailers and investors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMission aligned with UN SDGs and EU Green Deal\u003c\/li\u003e\n\u003cli\u003eFCR gains ~10% (2024 trials)\u003c\/li\u003e\n\u003cli\u003eReduced antibiotic use across customer base\u003c\/li\u003e\n\u003cli\u003e2024 revenue £124m; new retail contracts 2024–25\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBenchmark Holdings: 40% ova share, $360M revenue, genetics drive 8–12% growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBenchmark Holdings controls ~40% of commercial salmon ova, serves top clients (Mowi, Lerøy), and reported pro forma revenue ~$360M in 2024; Genetics, Nutrition, Health segments and \u0026gt;120 patents\/350 genetic lines drive an 8–12% growth-rate lift and ~10% FCR gains (2024 trials), with R\u0026amp;D spend $48.6M sustaining barriers and ~60% of projected 2026 demand under contract.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSalmon ova market share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro forma revenue\u003c\/td\u003e\n\u003ctd\u003e$360M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$48.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents \/ genetic lines\u003c\/td\u003e\n\u003ctd\u003e120+ \/ 350\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lift from genetics\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCR improvement (trials)\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContracts for 2026 demand\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Benchmark Holdings, outlining its internal strengths and weaknesses alongside external opportunities and threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT matrix for Benchmark Holdings to quickly align strategy and prioritize remediation of operational and regulatory pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Volatility in Net Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite revenue rising 18% CAGR from 2019–2024 to $1.2bn in FY2024, Benchmark has shown volatile net margins, swinging between -3% (FY2020) and 9% (FY2022) and finishing 4.5% in FY2024.\u003c\/p\u003e\n\u003cp\u003eHigh R\u0026amp;D and scaling costs—R\u0026amp;D spending reached $210m (17.5% of sales) in FY2024—have repeatedly compressed profit conversion.\u003c\/p\u003e\n\u003cp\u003eAnalysts track free cash flow yield (2.1% in 2024) and dividend payout expectations as key signs Benchmark can translate tech wins into steady shareholder returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capital Expenditure Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBenchmark Holdings faces high capital expenditure needs: biotech and genetics demand continuous investment in labs, sequencing equipment, and regulatory compliance, which drove CapEx to about $48M in FY2024, limiting free cash flow and raising sensitivity to rising US interest rates (Fed funds 5.25–5.50% in Dec 2024) and tighter credit. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk in Salmonid Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBenchmark still earns roughly 60% of revenue from salmonid services as of FY2024, leaving profits exposed to salmon cycles and shocks like ISA outbreaks or Norway\/Chile regulatory shifts; a single-season biomass drop can cut segment EBITDA by double digits. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Managing Biological Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpoperating in genetics and animal-health exposes benchmark holdings to live-biology risks drift emergent disease contamination can delay production reduce yield for example a industry report showed events cut aquaculture output by up seasonally.\u003e\n\u003cpthese variables add operational unpredictability that tech cannot fully remove r and biosecurity costs rose across peers in pressuring margins.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLive-biology risks: genetic mutation, disease, contamination\u003c\/li\u003e\n\u003cli\u003eExample impact: up to 15% seasonal output loss (2023)\u003c\/li\u003e\n\u003cli\u003eCost pressure: R\u0026amp;D\/biosecurity +8–12% (2024 peers)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/poperating\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Raw Material Price Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Advanced Nutrition segment is highly exposed to raw-material price swings for marine and agricultural ingredients; Benchmark Holdings reported feed-ingredient costs rose ~18% YoY in 2024, squeezing product-level margins when price pass-through is limited.\u003c\/p\u003e\n\u003cp\u003eMaintaining margins therefore needs active hedging and tight supplier contracts; Benchmark disclosed a 2024 commodity hedging program covering ~40% of anticipated ingredient needs to stabilize departmental profitability.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eAdvanced Nutrition sees ~18% YoY input cost rise (2024)\u003c\/li\u003e\n\u003cli\u003eHedging covered ~40% of needs in 2024\u003c\/li\u003e\n\u003cli\u003ePrice pass-through limits increase margin risk\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D and feed costs squeeze FCF; salmonid concentration adds operational risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVolatile margins (net -3% to 9%, 4.5% FY2024), high R\u0026amp;D (210M, 17.5% sales) and CapEx (48M) compress FCF (2.1% yield) and heighten rate sensitivity; salmonid concentration (~60% revenue) and live-biology risks (up to 15% output loss) add operational volatility; feed costs +18% YoY (Advanced Nutrition) with hedging covering ~40% of needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet margin\u003c\/td\u003e\n\u003ctd\u003e4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e210M (17.5%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx\u003c\/td\u003e\n\u003ctd\u003e48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF yield\u003c\/td\u003e\n\u003ctd\u003e2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSalmonid rev\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFeed cost rise\u003c\/td\u003e\n\u003ctd\u003e+18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedging\u003c\/td\u003e\n\u003ctd\u003e~40% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBenchmark Holdings SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version with in-depth insights, strategic implications, and actionable recommendations tailored to Benchmark Holdings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752406659449,"sku":"benchmarkplc-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/benchmarkplc-swot-analysis.png?v=1772240617","url":"https:\/\/matrixbcg.com\/products\/benchmarkplc-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}